Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19349542 | 0.95 | RET (0.48) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL19349332 | 0.93 | NPC1 (0.42) | BRAFNPC1LMNAPKMRET | |
| SCHEMBL19349405 | 0.93 | BRAF (0.45) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL19349446 | 0.93 | RET (0.43) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL19349306 | 0.92 | BRAF (0.43) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL19349471 | 0.90 | RET (0.40) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL24081833 | 0.90 | BRAF (0.39) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL24081778 | 0.89 | BRAF (0.43) | BRAF | |
| SCHEMBL19349307 | 0.89 | RET (0.39) | BRAFNPC1LMNAPKMMAP3K20 | |
| SCHEMBL19349375 | 0.85 | RET (0.45) | BRAFRETCDK8KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430005-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3430005-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-09-21 | — | — | US | disclosed |
| WO-2017161045-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKAR2B, AKT3, MAP3K11 | BRAF 31/4885NPC1 2565/4885LMNA 1358/4885 |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PRKAR2B, AKT3, MAP3K11 | BRAF 31/4885NPC1 2565/4885LMNA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.